ADIPOQ antibody
Quick Overview for ADIPOQ antibody (ABIN1169203)
Target
See all ADIPOQ AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- anti-Adiponectin (mouse), pAb
-
Specificity
- Recognizes mouse adiponectin. Weakly cross-reacts with rat adiponectin. Detects a band of ~35 kDa by Western blot.
-
Cross-Reactivity (Details)
- Weakly cross-reacts with rat adiponectin.
-
Characteristics
- Polyclonal Antibody. Recognizes mouse adiponectin. Weakly cross-reacts with rat adiponectin. Detects a band of ~35 kDa by Western blot. Source: Rabbit. Applications: ELISA, IP, WB. Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives. ACRP30 was identified as a novel adipocyte-specific synthesized and secreted protein with structural resemblance to complement factor C1q. Like adipsin, ACRP30 secretion is induced ~10-fold during adipocyte differentiation. Plasma levels are reduced in obese humans, and low levels are associated with insulin-resistance. Treatment of db/db mice with TZD increased ACRP30 levels.
-
Sterility
- 0.2 μm filtered
-
Immunogen
- Recombinant mouse adiponectin.
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 0.2μm-filtered solution in PBS, pH 7.4.
-
Preservative
- Without preservative
-
Handling Advice
- After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
+4°C
-20°C
Stable for at least 6 months after receipt when stored at -20°C.
-
Expiry Date
- 6 months
-
-
- ADIPOQ (Adiponectin (ADIPOQ))
-
Alternative Name
- Adiponectin
-
Background
-
Alternate Names/Synonyms: ACRP30, AdipoQ, apM1, GBP28, Adipocyte Complement Related Protein of 30 kDa
Product Description: ACRP30 was identified as a novel adipocyte-specific synthesized and secreted protein with structural resemblance to complement factor C1q. Like adipsin, ACRP30 secretion is induced ~10-fold during adipocyte differentiation. Plasma levels are reduced in obese humans, and low levels are associated with insulin-resistance. Treatment of db/db mice with TZD increased ACRP30 levels.
-
UniProt
- Q60994
Target
-